Register for our free email digests:
Antares Pharma Inc.
Latest From Antares Pharma Inc.
Lipocine resubmits Tlando NDA with new study data supporting twice-daily fixed dosing regimen for the oral testosterone replacement candidate; FDA action expected by Feb. 8.
Kite's CAR-T application seems to be sailing ahead without US FDA AdComm review; large employers in the US look into value-based contracting while European regulators band together on joint price negotiations; Teva is back at FDA with its EpiPen application. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.
Keeping Track: Zelboraf Takes Breakthrough Path For Rare Blood Disease; Teva Resubmits Generic EpiPen
The latest drug development news and highlights from our US FDA Performance Tracker.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.
- Medical Devices
- Controlled Release
- Topical Delivery
- Drug Delivery
- Therapeutic Areas
- Gynecological, Urological
- Metabolic Disorders
- Medi-Ject Corp.
- North America
- Parent & Subsidiaries
- Antares Pharma Inc.
- Senior Management
Robert Apple, Pres. & CEO
Fred M Powell, SVP, CFO
Jonathan S Jaffe, MD, VP, Clin. Dev.
Greg DeFilippis, VP, Bus. Dev. & Alliances
Peter Sadowski, PhD, SVP, Tech and IP
John J Howarth, VP, Corp Affairs
Patrick Madsen, SVP, Ops
Keith Muckenhirn, Principal Financial/Principal Accounting Officer
Steven Knapp, SVP, Reg Affairs & QA
Edward Kessig, VP, Sales
Henry R Wolfe, PhD, SVP, Product Dev
- Contact Info
Antares Pharma Inc.
Phone: (609) 359-3020
100 Princeton S.
Ewing, NJ 08628
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.